மருத்துவர் நிச்சயதார்த்தம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medicines for colorectal, skin and ovarian cancers are among four newly approved treatements for use in NHS Scotland. The Scottish Medicines Consortium (SMC) announced it has accepted four new medicines for routine use from Monday including Encorafenib (Braftovi), hydrochloride (Ledaga), niraparib (Zejula) and Ravulizumab (Ultomiris). Encorafenib (Braftovi) was accepted for use along with the medicine cetuximab for the treatment of colorectal cancer in patients with a gene mutation called “BRAF V600”. It can be used when the cancer has spread elsewhere in the body after previously being treated with other medicines. Great news for advanced #bowelcancer patients with a BRAF mutation living in Scotland. The Scottish Medicines Consortium has today approved BRAFTOVI® (encorafenib). This new drug offers hope to patients with very limited treatment options: https://t.co/LcCiOc6IQApic.twitter.com/BkSzRHAvaF

United kingdomJanet grahamEncorafenib braftoviMark macgregorRavulizumab ultomirisScotland cancer centreBeatson westClinician engagementஒன்றுபட்டது கிஂக்டம்ஜேனட் கிரஹாம்குறி மேக்ரிகோர்ஸ்காட்லாந்து புற்றுநோய் மையம்பீட்சன் மேற்குமருத்துவர் நிச்சயதார்த்தம்